Frankel Stanley
Known title: DirectorCIK: 0001855726
Frankel Stanley's purchase track record
Frankel Stanley has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/28/2026 | DTIL | $6K | pending | pending | — |
| 12/16/2025 | DTIL | $13K | +43.8% | +30.9% | +10.5% |
| 9/26/2025 | DTIL | $13K | -16.4% | +19.0% | -4.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DTIL | ▲ Buy | Open Market | 1,000 | $6K | 9/28/2026 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 | View on chart |
| DTIL | ▲ Buy | Open Market | 2,700 | $13K | 12/16/2025 | View on chart |
| DTIL | ▲ Buy | Open Market | 2,700 | $13K | 9/26/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.